ArticlePEC innovation2026
HoloVAD; A feasibility study of a new patient education tool for patients with a left ventricular assist device.
Article in PEC innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Patient education for patients with a left ventricular assist device (LVAD) and their loved ones is crucial for improving adherence and reducing complications. HoloVAD is an innovative virtual education tool, which offers a preimplantation experience of life with an LVAD (Holomoves ©, The Netherlands). Our objective is Method: A cross-sectional, quantitative feasibility study was conducted among patients with an LVAD, and their loved ones. Results: In total 45 participants were included. Six out of the seven acceptability domains of the Unified Theory of Acceptance (UTAUT) were scored positively. With an excellent overall SUS-score (82.5) the HoloVAD application is assessed as usable for both groups, and tolerability is scored as positive at every point of the Virtual Reality Sickness Questionnaire (VRSQ), for both groups. Conclusion: HoloVAD is feasible - defined as being acceptable, usable, and tolerable -and represents a promising and helpful new education tool for the study population. Innovation: An LVAD is life-changing with high complication risks. HoloVAD is innovative because it integrates visualization and interaction through mixed reality, enabling a deeper understanding of life with an LVAD. This study highlights the feasibility of HoloVAD as a novel educational tool for patients and their loved ones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.